
Health Check: After decades of investor pain, Mesoblast faces ‘extraordinary
A year after its maiden product launch, Mesoblast is at a “defining and transformative point”EBR Systems sees green shoots after soft sales periodSyntara shares swoon after study setbackBiotech investors are realising…
Read report ↗





